18th PAGE Meeting

St. Petersburg - Russia
23-26 June, 2009

View abstracts

Home / 2009 – St. Petersburg – Russia / Abstracts

← Back to filters

Abstracts (11)

Rujia Xie1, Rosalin Arends2, Stephen Olson2 , and Scott Marshall1

Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of the Effect of Tanezumab on Overall Daily Pain Score Data in Adults with Moderate-to-Severe Pain due to Osteoarthritis of the Knee

Stacey Tannenbaum[2], Aurelie Gautier[1] & Philip Lowe[1]

Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and pediatric patients with moderate to severe persistent allergic (IgE-mediated) asthma

Philip Lowe, Aurelie Gautier

On the ability to predict free ligand suppression when free ligand assays are not available or impossible

Philip Lowe[1], Stacey Tannenbaum[2], Aurelie Gautier[1]

Omalizumab (Xolair) may normalise IgE production rate in patients with moderate-to-severe atopic asthma

Stacey Tannenbaum[1], Abhijit Chakraborty[1], Christiane Rordorf[2], Aurélie Gautier[2] & Philip Lowe[2]

Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes

Leonid Gibiansky (1), Tarundeep Kakkar (2), Peiming Ma (2)

Population Pharmacokinetics of AMG 317, a Fully Human Anti-IL-4Rα IgG2 Monoclonal Antibody Evaluated in Healthy and Asthmatic Subjects

E. Pigeolet (1), P. Wiczling (3), P. Lowe (1), S. Balser (2), A. Berghout (2) and W. Krzyzanski (4)

Artefactual inflation of pharmacokinetic difference between two Granulocyte Colony Stimulating Factor (G-CSF) drug products by non compartmental analysis.

Brigitte D. Lacroix(1,2), Mark Lovern(1), Armel Stockis(1), Maria Laura Sargentini-Maier(1), Mats O. Karlsson(2) and Lena E. Friberg(2)

Exposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol.

W. Krzyzanski (1), P. Kawczak (1), P. Wiczling (2), P. Lowe (3), E. Pigeolet (3), F. Ludicke (4), S. Balser (4).

Receptor Mediated Disposition PK/PD Model of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations.

E. Rouits, M. Lovern, M.L. Sargentini-Maier

Target-Mediated Drug Disposition Model to Describe Non-linear Kinetics of a Monoclonal Antibody

Helene Karcher, Phil Lowe

Harnessing clinical knowledge on ligand-targeting drug to develop a new compound targeting the associated receptor : an example of model-based biologics design in pre-clinical development